Protara Therapeutics, Inc. announced the appointment of Barry P. Flannelly, Pharm.D, to its Board of Directors. Dr. Flannelly, who currently serves as Executive Vice President, General Manager, North America, at Incyte, brings to Protara over 20 years of commercial and business development leadership experience across numerous leading pharmaceutical and biotech companies.

NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases

Get the inside scoop on jobs, salaries, top office locations, and CEO insights. Compare pay for popular roles and read about the team’s work-life balance. Uncover why Protara Therapeutics, Inc. is the best company for you. Protara is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. Business Areas: Small Molecules, Rare Diseases Protara Therapeutics | Biotech Careers The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. At Protara, we believe only by reflecting the world in which we live can we truly understand and treat cancer and rare diseases with significant unmet needs which often know no boundaries of age, gender, race, religion or 2021-03-12 · Protara is an Equal Opportunity Employer and is committed in policy and in practice to recruit, hire, train, and promote in all job qualifications without regard to race, color, religion, gender, age, national origin, citizenship status, marital status, sexual orientation, gender identity, disability and veteran status and any other protected characteristics under federal, state, or local laws.

LifeSci Communications koshea@lifescicomms.com 929-469-3860 Protara Therapeutics Announces Appointment of Barry P. Flannelly to Board of Directors - read this article along with other careers information, tips and advice on BioSpace Protara Therapeutics, Inc. announced the appointment of Barry P. Flannelly, Pharm.D, to its Board of Directors. NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the appointment of Cynthia Smith to its Board of Directors. NEW YORK (AP) _ Protara Therapeutics, Inc. (TARA) on Thursday reported a loss of $8.8 million in its fourth quarter. The New York-based company said it had a loss of 79 cents per share. About Protara Therapeutics Inc Protara Therapeutics, Inc. is a clinical-stage company engages in developing treatments for rare and specialty diseases with significant unmet needs. Protara Therapeutics | 1,037 followers on LinkedIn. Steadfast and tenacious in our search for transformative therapies | Protara is committed to identifying and advancing transformative therapies 2021-03-11 · NEW YORK (AP) _ Protara Therapeutics, Inc. (TARA) on Thursday reported a loss of $8.8 million in its fourth quarter.

Protara Therapeutics is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options.

Su Zhang. Executive Director, Strategy and Business Development at Protara Therapeutics Career Infinite升涯求职 - Business Development Representative.

Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the promotion of Jacqueline (Jackie) Zummo, Ph.D., MPH, MBA from Senior Vice President, Research and Development Operations to Chief Scientific Operations NEW YORK, July 24, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced the appointment of Barry P. Flannelly, Pharm.D, to its Board of Directors. Protara Therapeutics develops transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy created for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid 2021-03-11 · Protara Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Business Overview - read this article along with other careers information, tips and advice on BioSpace 2020-10-02 · View the latest Protara Therapeutics Inc. (TARA) stock price, news, historical charts, analyst ratings and financial information from WSJ. 2021-02-02 · NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases Company profile page for Protara Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information 2020-07-24 · About Protara Therapeutics, Inc. Protara is committed to identifying and advancing transformative therapies for people with rare and specialty diseases who have limited treatment options. Protara Therapeutics New York, NY 10010, USA Full Time Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver 2020-05-11 · Protara Therapeutics Blaine.Davis@protaratx.com 646-844-0337.

Su Zhang. Executive Director, Strategy and Business Development at Protara Therapeutics Career Infinite升涯求职 - Business Development Representative.

Protara's portfolio includes its lead program, TARA-002, See insights on Protara Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. View Jobs (4) A high-level overview of Protara Therapeutics, Inc. (TARA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and Current Job Openings · Business Development Clinical Development Commercial Finance & Accounting Human Resources Medical Affairs Research & Protara Therapeutics, Inc. Common Stock Time.

Unfortunately, we do not have a current market price available for Protara Therapeutics Inc NPV. In order to obtain the current price, 111 Medical Science Liaison Rare Disease jobs available on Indeed.com. Apply to Liaison Global Blood Therapeutics, Inc. (GBT) Protara Therapeutics, Inc. Find the latest Institutional Holdings data for Protara Therapeutics, Inc. Common Stock (TARA) at Nasdaq.com. Protara Therapeutics develops transformative therapies for people with cancer and rare diseases. Protara's portfolio includes its lead program, TARA-002, See insights on Protara Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. View Jobs (4) A high-level overview of Protara Therapeutics, Inc. (TARA) stock.
Koppla surfplatta till tv trådlöst

View Protara Therapeutics (protaratx.com) location in New York, United States , revenue, industry and description. Find related and similar companies as well as Market data not available. Unfortunately, we do not have a current market price available for Protara Therapeutics Inc NPV. In order to obtain the current price, 111 Medical Science Liaison Rare Disease jobs available on Indeed.com. Apply to Liaison Global Blood Therapeutics, Inc. (GBT) Protara Therapeutics, Inc. Find the latest Institutional Holdings data for Protara Therapeutics, Inc. Common Stock (TARA) at Nasdaq.com.

Uncover why Protara Therapeutics, Inc. is the best company for you. Protara is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. Business Areas: Small Molecules, Rare Diseases Protara Therapeutics | Biotech Careers The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options.
Management land

2021-03-29

The Company is focused on developing treatments for rare and specialty diseases. Its development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. 2021-03-31 · Stock analysis for Protara Therapeutics Inc (TARA:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Protara Therapeutics revenue from 2013 to 2020. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.

Pharmaceuticals Corp (Aktieinformation). Aktieinformation Zomedica Pharmaceuticals Corp Resultaten Zomedica Pharmaceuticals Corp · Grafiek Zomedica

2021-03-11 Nov. 12, 2020 -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs View the real-time TARA price chart on Robinhood and decide if you want to buy or sell commission-free. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Protara Therapeutics against related stocks people have also bought. NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) --ArTara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company identifying and advancing transformative therapies for people with rare and specialty diseases, today announced that it has changed its name to Protara Therapeutics, Inc., effective immediately.As part of the name change, the Company has launched a new corporate website, … 2020-10-02 Protara Therapeutics develops transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy created for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid Protara Therapeutics revenue from 2013 to 2020.

View Jobs (4) A high-level overview of Protara Therapeutics, Inc. (TARA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and Current Job Openings · Business Development Clinical Development Commercial Finance & Accounting Human Resources Medical Affairs Research & Protara Therapeutics, Inc. Common Stock Time. 00:00. Contact · Careers · Market Hours · Glossary. © 2020 OTC Markets Group Inc. Terms of Service Linking Protara Therapeutics, Inc. Company Intro. Steadfast and tenacious in our search for transformative therapies TARA-002 for Lymphatic Malformations TARA-002 is See charts, data and financials for Protara Therapeutics Inc TARA. Budgeting · Banking and Credit · Taxes · Family Finance · Debt · Careers.